MiNK Therapeutics Inc.

NASDAQ: INKT · Real-Time Price · USD
15.29
-0.03 (-0.20%)
At close: Aug 15, 2025, 3:59 PM
14.90
-2.55%
After-hours: Aug 15, 2025, 07:55 PM EDT

MiNK Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a -11.71B -11.71B -11.71B n/a 14.41B 15.98B 17.54B 5.83B 3.34B 1.78B 221.92M 221.92M n/a n/a n/a
Cost of Revenue
1.88B 1.88B 1.88B 5.22B 11.57B 17.42B 17.42B 20.18B 21.54B 23.06B 23.06B 28.45B 20.75B 13.38B 13.38B 16.19K 16.19K
Gross Profit
-1.88B -1.88B -13.59B -16.93B -23.28B -17.42B -3.01B -4.21B -4B -17.23B -19.72B -26.67B -20.53B -13.15B -13.38B -16.19K -16.19K
Operating Income
-7.46M -11.29M -14.29M -17.62M -20.9M -22.92M -25.31M -28.07M -29.43M -30.95M -29.42M -34.81M -32.72M -28.36M -23.52M -16.07M -14.13M
Interest Income
155.95K 172.57K 174.52K 203.79K 311.82K 463.26K 556.57K 542.24K 395.85K 227.79K 92.96K n/a n/a n/a n/a n/a 557.55K
Pretax Income
-2.77B -10.78M -13.78M -17.09M -20.59M -22.46M -24.77M -25.98M -25.9M -27.99M -25.99M -33.92M -34.14M -30.21M -25.98M -17.76M -15.75M
Net Income
-2.77B -10.78M -13.78M -17.09M -20.59M 145.76M 143.73M 144.27M 145.96M -24.75M -23.03M -32.71M -34.55M -30.21M -25.98M -17.76M -15.75M
Selling & General & Admin
1.27B 4.31M 5.64M 6.27M 7M 7.38M 7.32M 7.36M 7.4M 7.83M 8.12M 7.1M 6.14M 4.64M 1.97M 1.62M 1.32M
Research & Development
1.27B 6.34M 8.24M 11.13M 13.85M 15.49M 17.99M 20.71M 22.03M 23.12M 21.25M 18.44M 16.15M 13.97M 10.8M 9.97M 9.5M
Other Expenses
n/a n/a 350.34K 169.4K -10 -10 -15.36K 1.55M 3.11M 2.7M 2.72M -8.43M -9.99M -9.59M -9.59M n/a n/a
Operating Expenses
2.54B 11.23M 14.18M 17.52M 20.79M 22.87M 25.31M 28.07M 29.43M 30.95M 29.37M 25.53M 22.29M 18.61M 12.77M 11.6M 10.92M
Interest Expense
n/a n/a n/a n/a n/a n/a 160.36K 160.36K 186.74K 187.59K 28.77K 910.1K 1.69M 2.43M 3.12M 2.87M 2.07M
Selling & Marketing Expenses
n/a n/a -54.04K -54.04K -54.04K -54.04K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
7.46M 11.29M 14.29M 17.62M 20.9M 22.92M 25.31M 28.07M 29.43M 30.95M 29.37M 25.53M 22.29M 18.61M 12.77M 11.6M 10.92M
Income Tax Expense
n/a n/a -2 -2 -2 -168.22M -168.5M -170.25M -171.86M -3.24M -2.96M -1.21M 404.36K 1.55K n/a n/a n/a
Shares Outstanding (Basic)
3.96M 3.77M 3.74M 3.71M 3.46M 3.46M 3.45M 3.44M 3.4M 3.38M 3.38M 3.36M 3.35M 3.29M 3.29M 2.84M 2.84M
Shares Outstanding (Diluted)
3.96M 3.77M 3.95M 3.71M 3.46M 3.46M 3.45M 3.44M 3.4M 3.38M 3.38M 3.36M 3.35M 3.29M 3.29M 2.84M 2.84M
EPS (Basic)
-8.86 -2.96 -3.91 -4.93 -6 43.00 42.40 42.50 43.00 -7.3 -6.9 -9.8 -10.7 -9.7 -8.44 -6.24 -5.84
EPS (Diluted)
-8.84 -2.94 -3.88 -4.93 -6 43.00 42.40 42.50 43.00 -7.3 -6.9 -9.8 -10.7 -9.7 -8.44 -6.24 -5.84
EBITDA
-6.84M -10.62M -13.9M -17.25M -20.68M -22.72M -25.12M -27.91M -29.29M -30.83M -28.72M -34.12M -32.05M -27.79M -22.88M -14.9M -12.97M
EBIT
-7M -10.83M -14.12M -17.46M -20.9M -22.92M -25.31M -28.07M -29.43M -30.95M -28.82M -34.21M -32.13M -27.85M -22.94M -14.97M -13.03M
Depreciation & Amortization
161.61K 215.44K 215.14K 205.96K 212.76K 204.62K 188.98K 163.96K 140.36K 121.75K 107.65K 99.5K 88.84K 77.96K 70.26K 64.81K 59.21K